Literature DB >> 9146668

Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type.

U Ramp1, K Jaquet, P Reinecke, C Schardt, U Friebe, T Nitsch, N Marx, H E Gabbert, C D Gerharz.   

Abstract

PURPOSE: The aim of the present study was to analyze the contribution of different stimulatory and inhibitory growth factors to the deregulated proliferation of human RCCs.
MATERIALS AND METHODS: The expression of different growth factors and their corresponding receptors were analyzed by Northern blot, FACS, ELISA and immunocytochemistry in 13 permanent human RCC cell lines of the clear cell type. Moreover, the functional intactness of growth factor-related signal transduction pathways was investigated.
RESULTS: All RCC cell lines expressed EGF-receptor mRNA and protein and 10 cell lines secreted TGF-alpha. Exogeneously added TGF-alpha resulted in a significant (p < 0.05) stimulation of growth in 6 RCC cell lines and a significant (p < 0.05) inhibition of proliferation in 3 cell lines. PDGF B and the corresponding type beta receptor were expressed in a single cell line. mRNA expression of PDGF A and PDGF-alpha-receptor as well as IGF-1 and its receptor could not be detected in any cell line. Eleven RCC cell lines expressed TGF-beta 1 mRNA and in all cell lines TGF-beta 1 secretion into the supernatant could be demonstrated. Whereas all cell lines exhibited TGF-beta type II-receptor mRNA, type I-receptor mRNA could be detected only in 3 cell lines. TGF-beta type III-receptor was observed in 1 cell line. Exogeneously added TGF-beta1 resulted in a significant (p < 0.05) inhibition of proliferation in 7 RCC cell lines.
CONCLUSION: Clear cell RCCs exhibit a complex and heterogeneous expression pattern for various growth factors and their receptors. Growth factor secretion and intact signal transduction pathways in most clear cell RCCs facilitate an intricate modulation of RCC growth by autocrine and paracrine interactions between tumor cells and host tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146668

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.

Authors:  Jacqueline Vuky; Christina Isacson; Mehran Fotoohi; Jason dela Cruz; Henry Otero; Vincent Picozzi; Thomas Malpass; David Aboulafia; Andrew Jacobs
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

2.  Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.

Authors:  David A Schoenfeld; Royce Zhou; Sakellarios Zairis; William Su; Nicole Steinbach; Deepti Mathur; Ankita Bansal; Alexis L Zachem; Bertilia Tavarez; Dan Hasson; Emily Bernstein; Raul Rabadan; Ramon Parsons
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

Review 3.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

4.  Insulin-like growth factors and risk of kidney cancer in men.

Authors:  J M Major; M N Pollak; K Snyder; J Virtamo; D Albanes
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

Review 5.  TGF-β and microRNA Interplay in Genitourinary Cancers.

Authors:  Joanna Boguslawska; Piotr Kryst; Slawomir Poletajew; Agnieszka Piekielko-Witkowska
Journal:  Cells       Date:  2019-12-12       Impact factor: 6.600

6.  Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.

Authors:  Keiichi Kondo; William Y Kim; Mirna Lechpammer; William G Kaelin
Journal:  PLoS Biol       Date:  2003-12-22       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.